Insights from the Latest 13F Filing for Q2 2024 Ronald H. Muhlenkamp, the founder and president of Muhlenkamp & Company, Inc., and the portfolio manager for the MUHLX mutual fund, is renowned for his patient value investing approach. With an average holding period of 10 years, Muhlenkamp focuses on companies with robust financials, a return on equity (ROE) of at least 15%, and P/E ratios that are attractively lower than their ROE and growth rates. His investment philosophy centers on the long-term profitability and reliability of the "Business of Investing," maintaining a typical stance of full investment in corporate stocks. Warning! GuruFocus has detected 5 Warning Sign with MCK. Significant Portfolio Adjustments by Ronald Muhlenkamp Highlight Broadcom's Sharp Reduction Summary of New Buys Ronald Muhlenkamp (Trades, Portfolio)'s recent 13F filing revealed the addition of new stocks to his portfolio, including: iShares Bitcoin Trust (NASDAQ:IBIT), with 14,000 shares, making up 0.15% of the portfolio and valued at approximately $477,960. Key Position Increases During the second quarter of 2024, Muhlenkamp increased his stakes in several companies: Apple Inc (NASDAQ:AAPL) saw an addition of 235 shares, bringing the total to 62,839 shares. This adjustment increased the share count by 0.38% and had a 0.02% impact on the current portfolio, totaling $13,235,150 in value. Microchip Technology Inc (NASDAQ:MCHP) also saw an increase of 410 shares, bringing the total to 117,189 shares, representing a 0.35% increase in share count and a total value of $10,722,790. Summary of Sold Out Positions Muhlenkamp completely exited the following position in Q2 2024: Bristol-Myers Squibb Co (NYSE:BMY), where all 135,045 shares were sold, impacting the portfolio by -2.13%. Key Position Reductions Significant reductions were made in several holdings, including: Broadcom Inc (NASDAQ:AVGO), which saw a reduction of 7,756 shares, decreasing the share count by 48.83% and impacting the portfolio by -2.99%. The stock traded at an average price of $140.14 during the quarter and has returned 27.84% over the past three months and 52.87% year-to-date. Kirby Corp (NYSE:KEX) was reduced by 72,367 shares, a 42.74% decrease, impacting the portfolio by -2%. The stock's average trading price during the quarter was $111.71, with a return of 34.23% over the past three months and 65.12% year-to-date. Portfolio Overview As of the second quarter of 2024, Ronald Muhlenkamp (Trades, Portfolio)'s portfolio comprised 29 stocks. The top holdings included 7.04% in McKesson Corp (NYSE:MCK), 5.2% in EQT Corp (NYSE:EQT), 4.93% in NMI Holdings Inc (NASDAQ:NMIH), 4.85% in Rush Enterprises Inc (NASDAQ:RUSHA), and 4.84% in Berkshire Hathaway Inc (NYSE:BRK.B). The investments are primarily concentrated across eight industries: Energy, Technology, Financial Services, Industrials, Healthcare, Consumer Cyclical, Basic Materials, and Communication Services. Significant Portfolio Adjustments by Ronald Muhlenkamp Highlight Broadcom's Sharp Reduction Significant Portfolio Adjustments by Ronald Muhlenkamp Highlight Broadcom's Sharp Reduction This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
Significant Portfolio Adjustments by Ronald Muhlenkamp Highlight Broadcom's Sharp Reduction
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...